A PHASE II STUDY OF INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN-2 (RHIL-2) BY INTRAVENOUS OR SUBCUTANEOUS ADMINISTRATION IN SUBJECTS WITH HIV INFECTION ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) COMPARED TO HAART ALONE: